Dornase Alfa
Overview
Dornase Alfa is an enzyme, acts as a mucolytic, used through inhalation to assist the clearance of bronchial secretions in patients with cystic fibrosis. Chemically, Dornase Alfa is recombinant human deoxyribonuclease (rh-DNase) produced by genetic engeering. It acts as a mucolytichydrolyzes extracellular DNA that has accumulatedin sputum from decaying neutrophils. The exact mechanism of hydrolysis is unknown, but by cleaving extracellular DNA, it decreases the viscosity of the sputum which then improves mucociliary clearance of sputum. It also reduces the incidence of recurrent bacterial infections. Clinical trials report that patients given it have an increase in general perception of well-being and a decreased perception of dyspnea, frequency of cough and chest congestion. It was approved for use by the FDA in December 1993.
Categories
- 25 Drugs acting on the respiratory tract
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Dornase Alfa's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 2500 mg | 2500 (2500) | 24 hourly | Inh | 1 or over 21 years may benefit forms twice daily dosage. By inhalation of nebulised solution (by jet nebulised) |
Paedriatic Dosage (20kg)
|
| 2.5 mg | 2.5 (2.5) | 24 hourly | Inh | 1 or over 21 years may benefit forms twice daily dosage. Child over 5year by inhalation of nebulised |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Dornase Alfa is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Dornase Alfa
Back to top
Previous Drug Generic - Next Drug Generic